X

Drug Profile

Antithrombin III - Grifols

Alternative Names: AT-III; ATIII - Grifols; Thrombate; Thrombate III

Latest Information Update: 16 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Grifols
Developer Endpoint Health; Grifols
Class Alpha globulins; Anti-infectives; Anticoagulants; Antithrombins; Antithrombotics
Mechanism of Action Thrombin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Antithrombin III deficiency
Research Sepsis

Most Recent Events

24 Feb 2022 Endpoint Health in-licenses antithrombin III from Grifols
24 Feb 2022 Early research in Sepsis in USA (unspecified route)
24 Feb 2022 Endpoint Health plans to file an IND application with the US FDA for phase II trial in Sepsis in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com